Business Description
Fulgent Genetics Inc
NAICS : 621511
SIC : 8071
Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 24.79 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.04 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.73 | |||||
| Beneish M-Score | -2.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 199.9 | |||||
| 3-Year Book Growth Rate | 139 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.37 | |||||
| 9-Day RSI | 31.92 | |||||
| 14-Day RSI | 31.48 | |||||
| 6-1 Month Momentum % | -31.13 | |||||
| 12-1 Month Momentum % | -50.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.29 | |||||
| Quick Ratio | 5.2 | |||||
| Cash Ratio | 4.04 | |||||
| Days Inventory | 24.62 | |||||
| Days Sales Outstanding | 55.38 | |||||
| Days Payable | 36.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.4 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.69 | |||||
| Operating Margin % | 57.05 | |||||
| Net Margin % | 42.41 | |||||
| ROE % | 34.3 | |||||
| ROA % | 30.37 | |||||
| ROIC % | 52.4 | |||||
| ROC (Joel Greenblatt) % | 442.91 | |||||
| ROCE % | 45.36 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.08 | |||||
| PE Ratio without NRI | 3.08 | |||||
| Price-to-Owner-Earnings | 3.31 | |||||
| PS Ratio | 1.29 | |||||
| PB Ratio | 0.9 | |||||
| Price-to-Tangible-Book | 1.05 | |||||
| Price-to-Free-Cash-Flow | 3 | |||||
| Price-to-Operating-Cash-Flow | 2.81 | |||||
| EV-to-EBIT | 1.26 | |||||
| EV-to-Forward-EBIT | -29.13 | |||||
| EV-to-EBITDA | 1.21 | |||||
| EV-to-Forward-EBITDA | 13315.61 | |||||
| EV-to-Revenue | 0.74 | |||||
| EV-to-Forward-Revenue | 2.18 | |||||
| EV-to-FCF | 1.69 | |||||
| Price-to-Projected-FCF | 0.4 | |||||
| Price-to-Graham-Number | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 3.22 | |||||
| Earnings Yield (Greenblatt) % | 79.11 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FLGT
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 925.148 | ||
| EPS (TTM) ($) | 12.57 | ||
| Beta | 1.72 | ||
| Volatility % | 50.33 | ||
| 14-Day RSI | 31.48 | ||
| 14-Day ATR ($) | 1.552558 | ||
| 20-Day SMA ($) | 41.008 | ||
| 12-1 Month Momentum % | -50.2 | ||
| 52-Week Range ($) | 37.335 - 109.55 | ||
| Shares Outstanding (Mil) | 30.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulgent Genetics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulgent Genetics Inc Analysis
Share your researchHeadlines
See More
No news.